drugset / Trial / NCT03955939
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
RandomizedParallel-groupOpen-labelTreatment
Summary
The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
Timeline
- Start
- 2019-08-02
- Primary completion
- 2020-05-14
- Completion
- 2020-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK-01 | Unknown | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |